Rong Zhuoyi, He Xuan, Fan Tianjian, Zhang Haitao
Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.
J Funct Biomater. 2024 Dec 24;16(1):2. doi: 10.3390/jfb16010002.
Atherosclerosis, a pathological process propelled by inflammatory mediators and lipids, is a principal contributor to cardiovascular disease incidents. Currently, drug therapy, the primary therapeutic strategy for atherosclerosis, faces challenges such as poor stability and significant side effects. The advent of nanomaterials has garnered considerable attention from scientific researchers. Nanoparticles, such as liposomes and polymeric nanoparticles, have been developed for drug delivery in atherosclerosis treatment. This review will focus on how nanoparticles effectively improve drug safety and efficacy, as well as the continuous development and optimization of nanoparticles of the same material and further explore current challenges and future opportunities in this field.
动脉粥样硬化是一种由炎症介质和脂质推动的病理过程,是心血管疾病发生的主要原因。目前,药物治疗作为动脉粥样硬化的主要治疗策略,面临着稳定性差和副作用大等挑战。纳米材料的出现引起了科研人员的广泛关注。脂质体和聚合物纳米颗粒等纳米粒子已被开发用于动脉粥样硬化治疗中的药物递送。本综述将重点关注纳米粒子如何有效提高药物安全性和疗效,以及同一材料纳米粒子的不断发展和优化,并进一步探讨该领域当前面临的挑战和未来机遇。